inSoma Bio GTM brain

category

market profile

• text: Fat grafting can require repeat procedures when graft volume is insufficient or resorbed; inSoma is studying a biomatrix to address this challenge.
• text: An early feasibility safety study of Fractomer was listed as suspended in a registry record last updated June 2026, with two participants enrolled; confirm current status before any clinical outreach.
• text: Duke describes breast reconstruction as the initial focus, with facial reconstruction an area of exploration.

personas

• title: Reconstructive plastic surgeon
  pains:

  • Fat graft resorption and limited available donor volume may require multiple procedures
  • Needs reliable soft-tissue shape and integration
• title: Breast reconstruction service line leader
  pains:

  • Patients may face a lengthy series of reconstructive procedures
  • Must evaluate clinical evidence, procurement and regulatory status before adoption
• title: Academic reconstructive surgery investigator
  pains:

  • Needs evidence of safety and durable outcomes for emerging graft materials
  • Must design feasible studies and obtain regulatory approvals

icp

• text: US plastic and reconstructive surgery practices performing breast or facial reconstruction and fat grafting are prospective end users, subject to regulatory authorization.
• text: Academic medical centers and clinical investigators in reconstructive surgery are plausible early research partners; no specific account size is published.

message pillars

• text: Support reconstruction using the patient's own tissue.
• text: Design material to support co-injected tissue.
• text: Use a temperature-responsive material.
• text: Produce recombinant biomaterial without harvesting natural tissue.

objections

• objection: What evidence supports safety and durable reconstruction?
  response: Request published results and updated trial and regulatory status; the first-in-human safety study was listed as suspended in June 2026.
• objection: Is this available for routine clinical use?
  response: Confirm authorization and availability directly with the company and relevant regulators before discussing adoption.
• objection: How does this compare with an off-the-shelf allograft?
  response: Compare indications, evidence and handling; MTF's Renuva is also being studied in combination with Fractomer, so the relationship can be complementary.

competitors

• name: MTF Biologics
  website: https://www.mtfbiologics.org/our-products/detail/renuva?vanity=renuva
  why: Renuva provides an alternative adipose matrix for volume restoration, though the companies have also studied combination use.
• name: Lattice Medical
  why: Develops technology for adipose tissue reconstruction and is an adjacent alternative.

influencers

• name: Scott Hollenbeck
  url: https://insomabio.com/
  why: Co-founder, reconstructive surgeon and medical advisor with specialty society leadership.
• name: Stefan Roberts
  url: https://dukecapitalpartners.duke.edu/news/how-stefan-roberts-and-insoma-bio-are-upgrading-fat-grafting-with-duke-technology-and-support/
  why: Co-founder and CEO who discusses the fat-grafting application.

keywords

• soft tissue reconstruction biomaterial
• breast reconstruction fat grafting
• facial reconstruction biomatrix
• adipose tissue regeneration
• fat graft retention
• reconstructive surgery tissue scaffold

voice

• Science-led
• Patient-centered
• Clinically focused

signals

• text: A reconstructive surgery program is studying fat grafting retention or post-mastectomy reconstruction.
• text: An academic surgical department is seeking tissue engineering collaborations or clinical research on soft-tissue repair.

pricing

motion

channels

• scientific research
• medical conferences

confidence

Founders

• name: Stefan Roberts
  title: Founder
  role: Founder
• name: Ashutosh Chilkoti
  title: Founder
  role: Founder
  bio: I am a professor of Biomedical Engineering at Duke University, and currently the Chair of the department. I work on genetically encoded biomaterials, drug delivery and point-of-care diagnostics. I have cofounded 5 companies - PhaseBio (NASDAQ: PHAS), Sentilus (acquired by Immucor in 2014), Gateway Bio, Isolere Bio and inSoma Bio,